BiondVax Pharmaceuticals Ltd.

1.19-0.0327-2.67%Vol 27.07K1Y Perf -58.97%
Jun 28th, 2022 15:59 DELAYED
BID1.11 ASK1.20
Open1.19 Previous Close1.22
Pre-Market- After-Market-
 - -  - -%
Target Price
9.50 
Analyst Rating
Strong Buy 1.00
Potential %
698.32 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
5.96 
Earnings Rating
Neutral
Market Cap22.16M 
Earnings Date
22nd Jun 2022
Alpha-0.00 Standard Deviation0.26
Beta2.51 

Today's Price Range

1.161.22

52W Range

1.004.19

5 Year PE Ratio Range

-10.90-2.60

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
1.89%
1 Month
-5.95%
3 Months
-30.53%
6 Months
-50.90%
1 Year
-58.97%
3 Years
-78.77%
5 Years
-85.83%
10 Years
-

TickerPriceChg.Chg.%
BVXV1.19-0.0327-2.67
AAPL137.44-4.2200-2.98
GOOG2 251.43-81.0200-3.47
MSFT256.48-8.4100-3.17
XOM91.502.47002.77
WFC40.18-0.0600-0.15
JNJ176.94-5.1800-2.84
FB196.640.99000.51
GE65.88-0.8300-1.24
JPM115.82-0.5600-0.48
Earnings HistoryEstimateReportedSurprise %
Q01 20220.00-0.20-
Q04 2021-0.010.00100.00
Q02 2021--0.37-
Q04 2020--0.36-
Q03 2020--0.01-
Q02 2020-0.01-1.12-11 100.00
Q01 2020-0.01-0.08-700.00
Q04 2019--1.25-
Earnings Per EndEstimateRevision %Trend
6/2022 QR0.00100.00Positive
9/2022 QR-0.0197.37Positive
12/2022 FY-0.41--
12/2023 FY-0.45--
Next Report Date-
Estimated EPS Next Report-
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume27.07K
Shares Outstanding18.63K
Shares Float18.63M
Trades Count107
Dollar Volume32.18K
Avg. Volume75.70K
Avg. Weekly Volume56.29K
Avg. Monthly Volume42.48K
Avg. Quarterly Volume128.35K

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) stock closed at 1.2227 per share at the end of the most recent trading day (a 5.41% change compared to the prior day closing price) with a volume of 156.72K shares and market capitalization of 22.16M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 25 people. BiondVax Pharmaceuticals Ltd. CEO is Ron Babecoff.

The one-year performance of BiondVax Pharmaceuticals Ltd. stock is -58.97%, while year-to-date (YTD) performance is -47.97%. BVXV stock has a five-year performance of -85.83%. Its 52-week range is between 1 and 4.19, which gives BVXV stock a 52-week price range ratio of 5.96%

BiondVax Pharmaceuticals Ltd. currently has a PE ratio of -1.00, a price-to-book (PB) ratio of 4.77, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -45.45%, a ROC of -34.57% and a ROE of -235.42%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from BiondVax Pharmaceuticals Ltd., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. BiondVax Pharmaceuticals Ltd.’s next earnings report date is -.

The consensus rating of Wall Street analysts for BiondVax Pharmaceuticals Ltd. is Strong Buy (1), with a target price of $9.5, which is +698.32% compared to the current price. The earnings rating for BiondVax Pharmaceuticals Ltd. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BiondVax Pharmaceuticals Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BiondVax Pharmaceuticals Ltd. has a Sell technical analysis rating based on Technical Indicators (ADX : 22.10, ATR14 : 0.09, CCI20 : -41.79, Chaikin Money Flow : -0.15, MACD : -0.04, Money Flow Index : 58.36, ROC : -7.02, RSI : 45.18, STOCH (14,3) : 42.14, STOCH RSI : 1.00, UO : 43.39, Williams %R : -57.86), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BiondVax Pharmaceuticals Ltd. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

BiondVax Pharmaceuticals Ltd.

BiondVax Pharmaceuticals Ltd is engaged in the healthcare sector. Its main activity is the commercialization and manufacturing of flu vaccine. Its product is designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains. The company recently concluded two Phase I/II trials in which the multimeric-001 universal flu vaccine was shown to be safe and immunogenic.

CEO: Ron Babecoff

Telephone: +972 89302529

Address: Hadassah Ein Kerem Campus, Jerusalem 74036, , IL

Number of employees: 25

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

54%46%

Bearish Bullish

67%33%

Bearish Bullish

61%39%

News

Stocktwits